eMedicine Specialties > Dermatology > Benign Neoplasms

Mastocytosis

Author: Daniel J Hogan, MD, Affiliate Teaching Faculty, Sun Coast Hospital; Investigator, Hill Top Research, Florida Research Center
Coauthor(s): Virginia Pylant Lewis, MD, Consulting Staff, Dermatology Associates
Contributor Information and Disclosures

Updated: Jan 8, 2008

Introduction

Background

Mastocytosis is a disorder characterized by mast cell proliferation and accumulation within various organs, most commonly the skin.

The World Health Organization (WHO) classification of mastocytosis includes the following1,2 :

  • Cutaneous mastocytosis
    • Urticaria pigmentosa 
    • Maculopapular cutaneous mastocytosis 
    • Diffuse cutaneous mastocytosis 
    • Mastocytoma of skin
  • Indolent systemic mastocytosis
  • Systemic mastocytosis with an associated (clonal) hematologic non–mast cell lineage disease
  • Aggressive systemic mastocytosis
  • Mast cell leukemia
  • Mast cell sarcoma
  • Extracutaneous mastocytoma1,2
This article focuses on cutaneous mastocytosis (CM). Types of CM include solitary mastocytoma, diffuse erythrodermic mastocytosis, paucicellular mastocytosis (also termed telangiectasia macularis eruptiva perstans [TMEP]), and urticaria pigmentosa (UP). UP is the most common form and is characterized by oval or round red-brown macules, papules, or plaques ranging in number from a few to thousands (see Media Files 1-2). Lesions may vesiculate in infancy (see Media File 3).

When a UP or mastocytoma lesion is stroked, it typically urticates, becoming pruritic, edematous, and erythematous. This change is referred to as the Darier sign, which is explainable on the basis of mast cell degranulation induced by physical stimulation. Uncontrolled stroking of mastocytomas should be avoided in patients who have had a systemic reaction such as miosis and asthmalike symptoms in their past.3

Pathophysiology

Whether mastocytosis is a hyperplastic reaction to an unknown stimulus or whether it is a neoplastic condition is unknown. Increased local concentrations of soluble mast cell growth factor in lesions of CM are believed to stimulate mast cell proliferation, melanocyte proliferation, and melanin pigment production. The induction of melanocytes explains the hyperpigmentation that commonly is associated with cutaneous mast cell lesions. Impaired mast cell apoptosis has been postulated to be involved, as evidenced by up-regulation of the apoptosis-preventing protein BCL-2 demonstrated in patients with mastocytosis. Activating mutations of the proto-oncogene c-kit have been identified but do not explain the initiation of the disease.4 Interleukin 6 levels have been shown to be elevated and correlated with disease severity, indicating interleukin 6 is involved in the pathophysiology of mastocytosis.5

Associated systemic manifestations are believed to reflect the release of mast cell–derived mediators, such as histamine, prostaglandins, heparin, neutral proteases, and acid hydrolases. Symptoms and signs induced by mediators may include headache, flushing, dizziness, tachycardia, hypotension, syncope, anorexia, nausea, vomiting, abdominal pain, and diarrhea. The skeletal, hematopoietic, gastrointestinal (GI), cardiopulmonary, and central nervous systems may be involved either directly, via mast cell infiltration, or indirectly, via mast cell mediator release.

Frequency

United States

Of new patients visiting dermatology clinics, 0.1-0.8% have some form of mastocytosis.

International

The international incidence is not known to differ from the incidence observed in the United States.

Mortality/Morbidity

Most cases of UP in children resolve spontaneously, although acute extensive degranulation rarely can cause life-threatening episodes of shock. Patients with adult-  or adolescent-onset UP are more likely to have persistent disease and are at greater risk for systemic involvement. Juvenile-onset systemic mastocytosis has a malignant transformation rate as high as 7%, while adult-onset systemic mastocytosis has a malignant transformation rate as high as 30%.

Race

Most reported cases are in whites. The cutaneous lesions of most types of mastocytosis are less visible in persons with more heavily pigmented skin.

Sex

Mastocytosis affects males and females equally (no known sex predilection).

Age

Most patients with mastocytosis are children; 75% of cases occur during infancy or early childhood. Incidence peaks again in patients aged 30-49 years.

Clinical

History

Patients may present with cutaneous lesions, systemic symptoms of an acute nature, and/or chronic systemic symptoms.

  • Most patients have pruritic cutaneous lesions.
  • Some patients, especially those with extensive cutaneous disease, experience acute systemic symptoms exacerbated by certain activities or ingestion of certain drugs or foods. Possible systemic symptoms include flushing, headache, dyspnea, wheezing, rhinorrhea, nausea, vomiting, diarrhea, and syncope.
  • Patients also may have chronic systemic symptoms involving various organ systems.
    • Involvement of the skeletal system may be manifested as bone pain or the new onset of a fracture.
    • Involvement of the central nervous system may produce neuropsychiatric symptoms, as well as nonspecific changes such as malaise and irritability.
    • GI involvement may yield weight loss, diarrhea, nausea/vomiting, and abdominal cramps.
    • Cardiovascular effects can include shock, syncope (resulting from vascular dilatation), or angina.
    • Anaphylactic reactions to hymenoptera stings may be the first sign of mastocytosis.

Physical

The most common physical findings in mastocytosis involve the skin, liver, spleen, and cardiovascular system.

  • Skin - Lesion types
    • Macules, papules, nodules, and plaques (see Media File 4)
    • Blisters and bullae in children (see Media File 5)
    • Diffuse induration
    • Isolated nodule or tumor
  • Skin - Distribution
    • Widespread symmetric distribution
    • Trunk involved more than extremities
    • Tendency to spare the face, scalp, palms, and soles; however, a patient with scarring alopecia has been reported6
  • Skin - Lesion color, quantity, and size 
    • Yellow-tan to red-brown
    • From 1 to more than 1000
    • From 1 mm to several centimeters
  • Skin - Special characteristics
    • Darier sign: Wheal and surrounding erythema develop in a lesion after rubbing it.
    • Dermatographism: In approximately half the patients, stroking macroscopically uninvolved skin produces dermographia.
    • Flushing: Flushing may occur spontaneously following skin stroke or after ingesting a mast cell degranulating agent.
  • Liver - Possible hepatomegaly (present in 40% of adult patients with systemic mastocytosis)
  • Spleen - Possible splenomegaly (present in 50% of patients with systemic mastocytosis)
  • Cardiovascular - Hypotension and tachycardia

Causes

Mastocytosis probably is a hyperplastic response to an abnormal stimulus. Rare cases of familial UP have been recorded.7

More on Mastocytosis

Overview: Mastocytosis
Differential Diagnoses & Workup: Mastocytosis
Treatment & Medication: Mastocytosis
Follow-up: Mastocytosis
Multimedia: Mastocytosis
References
[ CLOSE WINDOW ]

References

  1. Valent P. Diagnostic evaluation and classification of mastocytosis. Immunol Allergy Clin North Am. Aug 2006;26(3):515-34. [Medline].

  2. Patnaik MM, Rindos M, Kouides PA, Tefferi A, Pardanani A. Systemic mastocytosis: a concise clinical and laboratory review. Arch Pathol Lab Med. May 2007;131(5):784-91. [Medline].

  3. Bussmann C, Hagemann T, Hanfland J, Haidl G, Bieber T, Novak N. Flushing and increase of serum typtase after mechanical irritation of a solitary mastocytoma. Eur J Dermatol. Jul-Aug 2007;17(4):332-4. [Medline].

  4. Noack F, Escribano L, Sotlar K, Nunez R, Schuetze K, Valent P, et al. Evolution of urticaria pigmentosa into indolent systemic mastocytosis: abnormal immunophenotype of mast cells without evidence of c-kit mutation ASP-816-VAL. Leuk Lymphoma. Feb 2003;44(2):313-9. [Medline].

  5. Brockow K, Akin C, Huber M, Metcalfe DD. IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosis. Clin Immunol. May 2005;115(2):216-23. [Medline].

  6. Xu X, Solky B, Elenitsas R, Cotsarelis G. Scarring alopecia associated with mastocytosis. J Cutan Pathol. Oct 2003;30(9):561-5. [Medline].

  7. Lappe U, Aumann V, Mittler U, Gollnick H. Familial urticaria pigmentosa associated with thrombocytosis as the initial symptom of systemic mastocytosis and Down's syndrome. J Eur Acad Dermatol Venereol. Nov 2003;17(6):718-22. [Medline].

  8. Butterfield JH. Systemic mastocytosis: clinical manifestations and differential diagnosis. Immunol Allergy Clin North Am. Aug 2006;26(3):487-513. [Medline].

  9. Schwartz LB. Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol Allergy Clin North Am. Aug 2006;26(3):451-63. [Medline].

  10. Verma KK, Bhat R, Singh MK. Bullous mastocytosis treated with oral betamethasone therapy. Indian J Pediatr. Mar 2004;71(3):261-3. [Medline].

  11. Kinsler VA, Hawk JL, Atherton DJ. Diffuse cutaneous mastocytosis treated with psoralen photochemotherapy: case report and review of the literature. Br J Dermatol. Jan 2005;152(1):179-80. [Medline].

  12. Wilson TM, Metcalfe DD, Robyn J. Treatment of systemic mastocytosis. Immunol Allergy Clin North Am. Aug 2006;26(3):549-73. [Medline].

  13. Krishnan K, Ramu V, Krishnaswamy G, Vardhana H. Mastocytosis, Systemic. eMedicine from WebMD [serial online]. December 18, 2006;Accessed November 1, 2007. Available at http://www.emedicine.com/MED/topic1401.htm.

  14. Allison MA, Schmidt CP. Reactivated urticaria pigmentosa. Cutis. Jul 1998;62(1):47-8. [Medline].

  15. Braverman IM. Skin Signs of Systemic Disease. 3rd ed. Philadelphia, Pa: WB Saunders; 1998:341-3.

  16. Brockow K, Scott LM, Worobec AS, Kirshenbaum A, Akin C, Huber MM, et al. Regression of urticaria pigmentosa in adult patients with systemic mastocytosis: correlation with clinical patterns of disease. Arch Dermatol. Jun 2002;138(6):785-90. [Medline].

  17. Eichenfield LF, Honig PJ. Blistering disorders in childhood. Pediatr Clin North Am. Aug 1991;38(4):959-76. [Medline].

  18. Emanuel PD, Barton JC, Gualtieri RJ, Sams WM Jr. Urticaria pigmentosa and preleukemia: evidence for reactive mast cell proliferation. J Am Acad Dermatol. May 1991;24(5 Pt 2):893-7. [Medline].

  19. Fitzpatrick TB, Johnson RA, Wolff K. Color Atlas and Synopsis of Clinical Dermatology. 3rd ed. New York, NY: McGraw-Hill; 1997:562-5.

  20. Freedberg IM, Eisen AZ, Wolff K, eds. Fitzpatrick's Dermatology in General Medicine. 5th ed. New York, NY: McGraw-Hill; 1999:1902-8.

  21. Gobello T, Mazzanti C, Sordi D, Annessi G, Abeni D, Chinni LM, et al. Medium- versus high-dose ultraviolet A1 therapy for urticaria pigmentosa: a pilot study. J Am Acad Dermatol. Oct 2003;49(4):679-84. [Medline].

  22. Habif TP. Clinical Dermatology: A Color Guide to Diagnosis and Therapy. 3rd ed. Philadelphia, Pa: Mosby; 1996:144-5.

  23. Hartmann K, Artuc M, Baldus SE, Zirbes TK, Hermes B, Thiele J, et al. Expression of Bcl-2 and Bcl-xL in cutaneous and bone marrow lesions of mastocytosis. Am J Pathol. Sep 2003;163(3):819-26. [Medline].

  24. Hartmann K, Henz BM. Mastocytosis: recent advances in defining the disease. Br J Dermatol. Apr 2001;144(4):682-95. [Medline].

  25. Has C, Misery L, David L, Cambazard F. Recurring staphylococcal scalded skin syndrome-like bullous mastocytosis: the utility of cytodiagnosis and the rapid regression with steroids. Pediatr Dermatol. May-Jun 2002;19(3):220-3. [Medline].

  26. Horny HP, Sotlar K, Valent P. Mastocytosis: state of the art. Pathobiology. 2007;74(2):121-32. [Medline].

  27. Jordon RE. Immunologic Diseases of the Skin. East Norwalk, Conn: Appleton & Lange; 1991:245-8.

  28. Kastrup EK. Drug Facts and Comparisons. St. Louis, Mo: Facts and Comparisons; 1998:1153-6, 1597-1600, 2057-67.

  29. Leaf FA, Jaecks EP, Rodriguez DR. Bullous urticaria pigmentosa. Cutis. Nov 1996;58(5):358-60. [Medline].

  30. Lever WF. Histopathology of the Skin. 8th ed. Philadelphia, Pa: Lippincott-Raven; 1997:141-3.

  31. Longley J, Duffy TP, Kohn S. The mast cell and mast cell disease. J Am Acad Dermatol. Apr 1995;32(4):545-61; quiz 562-4. [Medline].

  32. Matsumoto M, Ikeda M, Takeya M, Kodama H. Plane xanthoma associated with multiple mastocytoma. Pediatr Dermatol. Sep-Oct 2007;24(5):E66-9. [Medline].

  33. Roberts LJ 2nd, Sweetman BJ, Lewis RA, Austen KF, Oates JA. Increased production of prostaglandin D2 in patients with systemic mastocytosis. N Engl J Med. Dec 11 1980;303(24):1400-4. [Medline].

  34. Schachner LA, Hansen RC. Pediatric Dermatology. 2nd ed. New York, NY: Churchill Livingstone; 1995:852-8.

  35. Soter NA. The skin in mastocytosis. J Invest Dermatol. Mar 1991;96(3):32S-38S; discussion 38S-39S. [Medline].

  36. Van Gysel D, Oranje AP, Vermeiden I, de Lijster de Raadt J, Mulder PG, van Toorenenbergen AW. Value of urinary N-methylhistamine measurements in childhood mastocytosis. J Am Acad Dermatol. Oct 1996;35(4):556-8. [Medline].

  37. van Toorenenbergen AW, Oranje AP. Comparison of serum tryptase and urine N-methylhistamine in patients with suspected mastocytosis. Clin Chim Acta. Sep 2005;359(1-2):72-7. [Medline].

  38. Vlieg-Boerstra BJ, van der Heide S, Oude Elberink JN, Kluin-Nelemans JC, Dubois AE. Mastocytosis and adverse reactions to biogenic amines and histamine-releasing foods: what is the evidence?. Neth J Med. Jul-Aug 2005;63(7):244-9. [Medline].

[ CLOSE WINDOW ]

Further Reading

[ CLOSE WINDOW ]

Keywords

mastocytoma, telangiectasia macularis eruptiva perstans, TMEP, urticaria pigmentosa, mast cell proliferation

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Daniel J Hogan, MD, Affiliate Teaching Faculty, Sun Coast Hospital; Investigator, Hill Top Research, Florida Research Center
Daniel J Hogan, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Contact Dermatitis Society, and Canadian Dermatology Association
Disclosure: Nothing to disclose.

Coauthor(s)

Virginia Pylant Lewis, MD, Consulting Staff, Dermatology Associates
Virginia Pylant Lewis, MD is a member of the following medical societies: American Medical Association, American Medical Student Association/Foundation, and Southern Medical Association
Disclosure: Nothing to disclose.

Medical Editor

Timothy McCalmont, MD, Director, UCSF Dermatopathology Service, Professor of Clinical Pathology and Dermatology, Departments of Pathology and Dermatology, University of California at San Francisco
Timothy McCalmont, MD is a member of the following medical societies: Alpha Omega Alpha, American Medical Association, American Society of Dermatopathology, California Medical Association, College of American Pathologists, and United States and Canadian Academy of Pathology
Disclosure: Apsara Consulting fee Independent contractor

Pharmacy Editor

Richard P Vinson, MD, Assistant Clinical Professor, Department of Dermatology, Texas Tech University School of Medicine; Consulting Staff, Mountain View Dermatology, PA
Richard P Vinson, MD is a member of the following medical societies: American Academy of Dermatology, Association of Military Dermatologists, Texas Dermatological Society, and Texas Medical Association
Disclosure: Nothing to disclose.

Managing Editor

Rosalie Elenitsas, MD, Associate Professor of Dermatology, University of Pennsylvania School of Medicine; Director, Penn Cutaneous Pathology Services, Department of Dermatology, University of Pennsylvania Health System
Rosalie Elenitsas, MD is a member of the following medical societies: American Society of Dermatopathology
Disclosure: Nothing to disclose.

CME Editor

Joel M Gelfand, MD, MSCE, Medical Director, Clinical Studies Unit, Assistant Professor, Department of Dermatology, Associate Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania
Joel M Gelfand, MD, MSCE is a member of the following medical societies: Society for Investigative Dermatology
Disclosure: AMGEN Consulting fee Consulting; AMGEN Grant/research funds None; Genentech Consulting fee Consulting; Centocor Consulting fee Consulting; Centocor Grant/research funds None; Covance Consulting fee Consulting; Shire  Consulting

Chief Editor

Dirk M Elston, MD, Director, Department of Dermatology, Geisinger Medical Center
Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.